Showing results (101-110 of 122) with videos related to
Sort By:
Pageof 13
Gastroenterologie Clinique Et Biologique|June 29, 1999
[Contribution of telemedicine applied to digestive cancer]A Sézeur, A de Gramont, E Touboul, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 6, 2001
Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR)F Maindrault-Goebel, A de Gramont, C Louvet, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2000
Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use programS Brienza, M A Bensmaïne, P Soulié, et al.Annales De Chirurgie|January 1, 1997
[Early debulking surgery after chemotherapy in advanced cancer of the ovary]A de Gramont, A Pigné, C Louvet, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2004
Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR studyT André, C Tournigand, O Rosmorduc, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 26, 2009
FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 studyB Chibaudel, C Tournigand, P Artru, et al.Seminars in Oncology|March 29, 2001
Randomized adjuvant study comparing two schemes of 5-fluorouracil and leucovorin in stage B2 and C colon adenocarcinoma: study design and preliminary safety results. Groupe d'Etude et de Recherche Clinique en Oncologie RadiotherapiesT André, P Colin, C Louvet, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 20, 2022
Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR)D Basile, C Broudin, J F Emile, et al.Clinical Nutrition ESPEN|November 13, 2020
Bariatric surgery affects obesity-related protein requirementsC Guillet, A Masgrau, A Mishellany-Dutour, et al.American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|April 16, 2014
Autologous dendritic cells prolong allograft survival through Tmem176b-dependent antigen cross-presentationM Segovia, C Louvet, P Charnet, et al.Pageof 13